Although it is effective in reducing tumor mass and prostate-specific antigen (PSA) levels (9), limitations to the use of adjuvant ADT in these localized tumors mainly derive from the short- and long-term adverse effects (AEs), which may worsen the quality of life of the patient or be potentially harmful (10–12). The gene discussed is KLK3; the disease is neoplasm.